Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
Journal
Infectious Diseases and Therapy
Start Page
Article number 100705
ISSN
2193-8229
2193-6382
Date Issued
2025-04-10
Author(s)
Chung-Feng Huang
Jeong Heo
Rong-Nan Chien
Yang-Hyun Baek
Ju-Hyun Kim
Ting-Tsung Chang
Kwan-Soo Byun
Jyh-Jou Chen
Sook-Hyang Jeong
Tsung-Hui Hu
Young-Seok Kim
Cheng-Yuan Peng
Won-Young Tak
Horng-Yuan Wang
Seung-Kew Yoon
I.-Shyan Sheen
Yu-Chun Hsu
Hyung-Joon Yim
Pei-Chien Tsai
Ming-Lun Yeh
Sang-Hoon Ahn
Chia-Yen Dai
Seung-Woon Paik
Jee-Fu Huang
Yoon-Jun Kim
Wan-Long Chuang
Young-Suk Lim
Ming-Lung Yu
Abstract
BACKGROUND/AIMS: Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C virus (HCV) infection. The long-term hepatic and extrahepatic outcomes of DAAs in chronic hepatitis C (CHC) patients receiving curative antivirals are elusive. METHODS: CHC patients were retrieved from two phase III sofosbuvir-based clinical trials conducted from 2013-2014. Patients who achieved a sustained virological response have been followed prospectively for 5 years since 2016. A propensity score-matched interferon-based historical control with a 1:3 ratio was used for comparison. Quality of life (QoL) was measured by the SF-36, liver fibrosis was measured by electrography, and fibrosis-related markers were followed annually in the prospective cohort. RESULTS: = 0.02) over 5 years. A significant decrease in QoL was observed in role limitations due to physical health and emotional problems, whereas the other parameters were maintained consistently throughout the 5 years of follow-up. CONCLUSIONS: HCV eradication by DAAs improved liver- and non-liver-related outcomes, constantly promoted liver fibrosis regression, and maintained quality of life after HCV cure. CLINICAL TRIAL NUMBER: NCT03042520.
SDGs
Publisher
Springer Science and Business Media LLC
Type
journal article